05/25/21 7:30 AMNasdaq : ASLN conferencesASLAN Pharmaceuticals to Participate In Fireside Chat at Jefferies Virtual Healthcare ConferenceASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced Dr Carl Firth, Chief Executive Officer of the company, willRHEA-AIneutral
05/11/21 7:30 AMNasdaq : ASLN earningsASLAN Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update ASLAN PharmaceuticalsRHEA-AIneutral
05/05/21 5:22 AMNasdaq : ASLN conferencesASLAN Pharmaceuticals to Present Data on ASLAN004 at Society for Investigative DermatologyASLAN Pharmaceuticals (NASDAQ: ASLN), a clinical-stage immunology focused biopharmaceutical companyRHEA-AIneutral
04/22/21 7:51 AMNasdaq : ASLN earningsASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage immunology focused biopharmaceutical companyRHEA-AInegative
03/18/21 7:27 AMNasdaq : ASLN managementASLAN Pharmaceuticals Appoints Dr Kathleen Metters as Independent DirectorASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced the appointment of Kathleen M. Metters, PhD, as an independentRHEA-AIneutral
03/03/21 12:42 AMNasdaq : ASLN offeringASLAN Pharmaceuticals Announces Pricing of Public Offering of American Depositary SharesASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced the pricing of an underwritten public offering of 15,000,000RHEA-AIneutral
03/01/21 4:01 PMNasdaq : ASLN offeringASLAN Pharmaceuticals Announces Proposed Public Offering of American Depositary SharesASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that it has commenced an underwritten public offering of $60.0RHEA-AIneutral
03/01/21 6:00 AMNasdaq : ASLN ASLAN Pharmaceuticals Announces Positive Interim Data From the Multiple Ascending Dose Study of ASLAN004 in Atopic Dermatitis- 74% average reduction in EASI from baseline at therapeutic doses after 8 weeks. 89% of patients achieved EASI-50 and 56% achieved EASI-90 - Data supportive of ASLAN004’s potential as a novel, first-in-class antibody targeting IL-13R with differentiated efficacy and safety profile in atopicRHEA-AIneutral
02/25/21 6:30 AMNasdaq : ASLN ASLAN Pharmaceuticals Announces $18 Million Private PlacementASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that it has entered into a securities purchase agreement to raiseRHEA-AIneutral
02/18/21 7:00 AMNasdaq : ASLN managementASLAN Pharmaceuticals Appoints Dr Neil Graham as Independent DirectorASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced the appointment of Neil Graham, MBBS, MD, MPH as an independentRHEA-AIneutral